Topotecan dose reduction. Apr 7, 2025 · Permanently reduce IV dose by 0.

Topotecan dose reduction. danicopan will increase the level or effect of topotecan by P-glycoprotein (MDR1) efflux transporter. List the risk factors for increased hematologic toxicity after topotecan therapy. 2 Recommended Dosage for Small Cell Lung Cancer The recommended dosage of Topotecan Injection medication page for healthcare professionals to search for scientific information on Pfizer medications We would like to show you a description here but the site won’t allow us. g. 1 Important Safety Information Verify dosage using body surface area. In principle all dose reductions due to adverse drug reactions should not be re-escalated in subsequent cycles without consultant approval. Prospective individualization of topotecan dosing may prevent or minimize dose-limiting myelosuppression and allow patients to achieve the maximum topotecan benefit by improving their ability to complete therapy with fewer treatment delays. Monitor peripheral blood counts frequently during treatment. Feb 17, 2020 · Includes Topotecan indications, dosage/administration, pharmacology, mechanism/onset/duration of action, half-life, dosage forms, interactions, warnings, adverse reactions, off-label uses and more. The main toxicities associated with topotecan are haematological, including neutropenia, thrombocytopenia, and anaemia; however, these toxicities are usually predictable, of short duration, noncumulative, and manageable with dose reduction and dose delay (Bochennek 2013; Safra 2013; Zighelboim 2013). Feb 1, 2004 · After completing this course, the reader will be able to: Describe the hematologic safety profile of topotecan in patients with relapsed ovarian cancer. 25 mg [to 1. We conducted a randomized phase II trial (TOWER [Topotecan Weekly Versus Conventional 5-Day Schedule in Patients With Platinum-Resistant Ovarian Cancer]) to better define the ratio between benefits Danicopan increases plasma concentrations of BCRP substrates; consider dose reduction of BCRP substrate according to its prescribing information. It is also a general rule for chemotherapy that if a third dose reduction is necessary treatment should be stopped. Discuss topotecan dose determination and the management of hematologic toxicity in higher-risk ovarian cancer patients. 25 mg/m (2)] or oral dose by 0. . 2. 4 mg/m (2) for subsequent courses OR Administer granulocyte-colony stimulating factor (G-CSF) following the subsequent course (before resorting to dose reduction) starting from day 6 of the course (24 hours after completion of topotecan administration). In clinical trials, topotecan was discontinued if the dose needed to be reduced below 1. Access and take the CME test online and Sep 6, 2017 · Alternatively, in the event of severe neutropenia, administer G-CSF (granulocyte-colony stimulating factor) following the subsequent course (before resorting to dose reduction) starting from day 6 of the course (24 hours after completion of topotecan administration). Haematological: G-CSF may be used to maintain neutrophil counts or dose reduction may be used as shown in table 1 for cycles 2-6 Nov 29, 2010 · Weekly administration of topotecan (Tw) is less toxic and widely considered a better treatment option than conventional 5-day therapy (Tc) in women with platinum-resistant recurrent ovarian cancer. 1, Dose adjustments may be necessary for other toxicities as well. , neutrophil counts less than 1,500 cells/mm3). Do not exceed a single dose of 4 mg intravenously. 5 mg/m2/day. If the myelosuppression recurs despite this dose reduction consider either stopping treatment or reducing the dose to 1. topotecan injection Dosage and Administration 2 DOSAGE AND ADMINISTRATION 2. Do not initiate topotecan treatment in patients with bone marrow suppression (e. 5mg/m2/day. Apr 7, 2025 · Permanently reduce IV dose by 0. Reduce or withhold topotecan dosing as recommended [see Dosage and Administration (2. hys iddv whin ao9x ugpmp5 no m0f ivmbnc 44lvjz igamm2